Long acting proteins and peptides and methods of making and using the same

Abstract

Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-γ, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.

1 .- 125 . (canceled) 
     
     
         126 . A method for refolding an insoluble or aggregated protein or peptide that lacks essential disulfides and that comprises one free cysteine residue, comprising the following steps:
 a) denaturing and reducing the protein or peptide in a solution comprising both a denaturing agent and a reducing agent, wherein said reducing agent does not form a mixed disulfide with the free cysteine in the protein or peptide, and wherein said reducing agent does not inactivate a thiol-reactive polyethylene glycol (PEG) or does not interfere with modification of the protein by a thiol-reactive PEG reagent;   b) refolding the protein by reducing the concentrations of the denaturing agent and reducing agents in the solution of (a) to levels sufficient to allow the protein or peptide to renature into a soluble, biologically active form;   c) wherein steps (a) and (b) occur in the absence of a cysteine blocking agent.   
     
     
         127 . The method of  claim 126 , wherein said denaturing agent is selected from the group consisting of: urea, guanidine and N-lauroyl sarcosine. 
     
     
         128 . The method of  claim 126 , wherein the reducing agent in step (a) is a reducing agent that does not contain a thiol moiety. 
     
     
         129 . The method of  claim 126 , wherein the reducing agent in step (a) is a phosphine reductant. 
     
     
         130 . The method of  claim 126 , wherein the reducing agent in step (a) is an alkyl phosphine. 
     
     
         131 . The method of  claim 130 , wherein the alkyl phosphine is selected from the group consisting of a butyl phosphine, a hydroxypropyl phosphine, a cyanoethyl phosphine, and a carboxyethyl phosphine. 
     
     
         132 . The method of  claim 130 , wherein the alkyl phosphine is selected from the group consisting of: tri-n-butylphosphine (TBP), tris(hydroxypropyl)phosphine (THP), tris(2-cyanoethyl)phosphine (TCNP), and tris(2-carboxyethyl)phosphine (TCEP), or a combination thereof. 
     
     
         133 . The method of  claim 126 , wherein said step (b) of refolding occurs in the presence of sufficient reducing agent to prevent the protein or peptide from forming disulfide bonds. 
     
     
         134 . The method of  claim 126 , wherein said step (b) of refolding comprises refolding the protein or peptide in the presence of glycerol. 
     
     
         135 . The method of  claim 126 , wherein said step (b) of refolding comprises refolding the protein or peptide in the presence of an oxidizing agent selected from the group consisting of oxygen, iodine, hydrogen peroxide, dihydroascorbic acid, tetrathionate, or O-iodosobenzoate. 
     
     
         136 . The method of  claim 126 , wherein step (b) of refolding comprises refolding the protein or peptide in the presence of a metal ion. 
     
     
         137 . The method of  claim 126 , further comprising isolating the refolded protein or peptide from other proteins and contaminants in the refold mixture. 
     
     
         138 . The method of  claim 137 , wherein the protein or peptide is isolated from other contaminants in the refold mixture by column chromatography. 
     
     
         139 . The method of  claim 138 , wherein the column chromatography buffers contain a reducing agent, wherein said reducing agent does not form a mixed disulfide with the free cysteine in the protein or peptide, and wherein said reducing agent does not inactivate a thiol-reactive polyethylene glycol (PEG) or does not interfere with modification of the protein by a thiol-reactive PEG reagent. 
     
     
         140 . The method of  claim 139 , wherein the reducing agent is the same reducing agent used in step (a). 
     
     
         141 . The method of  claim 138 , further comprising the step of exposing the protein or peptide to a cysteine-reactive moiety to obtain a cysteine-modified protein or cysteine-modified peptide, wherein the cysteine-reactive moiety is attached to at least one free cysteine in said isolated protein or peptide. 
     
     
         142 . The method of  claim 141 , wherein the step of exposing is conducted in the presence of a reducing agent. 
     
     
         143 . The method of  claim 142 , wherein the reducing agent is the same reducing agent used in step (a). 
     
     
         144 . The method of  claim 141 , wherein the cysteine-reactive moiety is selected from the group consisting of a polyethylene glycol, a polyvinyl pyrolidone, a carbohydrate, a dextran, a peptide, a lipid and a polysaccharide. 
     
     
         145 . The method of  claim 141 , wherein the cysteine-reactive moiety is a polyethylene glycol. 
     
     
         146 . The method of  claim 126 , wherein the protein is a cysteine variant of interferon-gamma (IFN-γ). 
     
     
         147 . The method of  claim 126 , wherein the insoluble or aggregated protein or peptide is a cysteine variant of a protein selected from the group consisting of: glucagon, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), gastric inhibitory peptide (GIP), PYY, PYY 3-36, exendin, ghrelin, gastrin, amylin, and oxyntomodulin. 
     
     
         148 . A method of treatment of a disease or condition in a patient in which a protein or peptide would be useful, comprising administering to the patient the protein or peptide, wherein the protein or peptide lacks essential disulfides, comprises one free cysteine residue and is insoluble or aggregated and wherein the protein or peptide has been refolded by a process, comprising:
 a) denaturing and reducing the protein or peptide in a solution comprising both a denaturing agent and a reducing agent, wherein said reducing agent does not form a mixed disulfide with the free cysteine in the protein or peptide, and wherein said reducing agent does not inactivate a thiol-reactive polyethylene glycol (PEG) or does not interfere with modification of the protein by a thiol-reactive PEG reagent;   b) refolding the protein by reducing the concentrations of the denaturing agent and reducing agents in the solution of (a) to levels sufficient to allow the protein or peptide to renature into a soluble, biologically active form;   c) wherein steps (a) and (b) occur in the absence of a cysteine blocking agent.